FindTrial
Sign In

Comparative Outcomes of OLIF and MIS Transforaminal Interbody Fusion in the Treatment of Degenerative Spondylolisthesis

Comparative Outcomes of OLIF and MIS Transforaminal Interbody Fusion in the Treatment of Degenerative Spondylolisthesis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019443
Enrollment
Unknown
Registered
2018-11-11
Start date
2015-01-01
Completion date
Unknown
Last updated
2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degenerative Spondylolisthesis

Interventions

Group 1:OLIF
Group 2:MISTLIF

Sponsors

The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: I-II Degenerative Spondylolisthesis

Exclusion criteria

Exclusion criteria: Tumors, fractures, infections, Degenerative Spondylolisthesis above III degree

Design outcomes

Primary

MeasureTime frame
area diameter of spinal canal;—

Countries

China

Contacts

Public ContactNi Wenfei

The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

shengsunren82330@126.com+86 0577 88002814

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 20, 2026